Company profile
CURIS INC
NASDAQ:CRISBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FIMEPINOSTAT | phase2 | — | 2 | no active trials |
| Cenopodlin | phase1 | — | 1 | no active trials |
| CUDC-101 | phase1 | — | 4 | completed, terminated |
| GDC-0917 | phase1 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00728793 | phase1 | completed | 2008-08-01 | 2010-04-01 | Curis, Inc. | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors |
| NCT01171924 | phase1 | completed | 2010-07-01 | 2011-10-01 | Curis, Inc. | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors |
| NCT02812875 | phase1 | completed | 2016-05-01 | 2020-05-07 | Curis, Inc. | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas |
| NCT07271667 | phase2 | recruiting | 2026-04-23 | 2027-11-01 | Curis, Inc. | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies |
| NCT03328078 | phase1_2 | recruiting | 2017-12-28 | 2026-08-01 | Curis, Inc. | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) |
FDA applications (0)
No records yet.